biostudies-literatureUnknown81Lambertini MPierre Fabre Médicament SAS<h4>Background</h4>Perceived risk and fear of recurrence in patients with breast cancer (BC) is a matter of concern and may affect their health behaviours and their ability to participate in decision making during their treatment. This survey aimed to examine perceptions and concerns of patients with HER2+ BC.<h4>Materials and methods</h4>A multi-country, non-interventional, direct-to-patient online survey was conducted between July 22, 2022 and March 1, 2023 in six European countries using a multi-modal recruitment approach.<h4>Results</h4>Out of 622 included patients, 96.8 % desired involvement in treatment decisions, and 58.5 % felt they had significant influence in the decision-making process. A total of 20.9 % of patients were unaware of their personal risk of recurrence, and 19.5 % rBreast (Edinburgh, Scotland)104456https://www.ebi.ac.uk/biostudies/studies/S-EPMC11992529biostudies-literaturePatient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey.PMC11992529Valachis ATredan OFontes-Sousa MMatos SKrone EBrice MGueroult-Accolas LLambertini MJackisch CBerjonneau EVidal MD'Antona RDialla ORuz MfalsePatient perception on risk of recurrence and decision-making in the management of HER2-positive early breast cancer: Insights from the ASKHER2 European survey.<h4>Background</h4>Perceived risk and fear of recurrence in patients with breast cancer (BC) is a matter of concern and may affect their health behaviours and their ability to participate in decision making during their treatment. This survey aimed to examine perceptions and concerns of patients with HER2+ BC.<h4>Materials and methods</h4>A multi-country, non-interventional, direct-to-patient online survey was conducted between July 22, 2022 and March 1, 2023 in six European countries using a multi-modal recruitment approach.<h4>Results</h4>Out of 622 included patients, 96.8 % desired involvement in treatment decisions, and 58.5 % felt they had significant influence in the decision-making process. A total of 20.9 % of patients were unaware of their personal risk of recurrence, and 19.5 % r2025-01-01T00:00:00Z2025 Mar2025-07-07T03:10:11.445Z2025-07-07T03:10:11.445ZS-EPMC119925294015849510.1016/j.breast.2025.104456